Skip to main content

Table 3 Maintenance of device mastery and inhalation errors after 12 weeks in the longitudinal phase

From: Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study

Outcome

BF Spiromax

(N = 151)

BF Turbuhaler

(N = 154)

Odds ratio (95% CI)

P-valuea

HCP-observed errors

 Patients without errors (inhalations 1 & 2) (co-primary endpoint), n (%)

89 (58.9)

82 (53.2)

1.26 (0.80–1.98)c

0.316

 Patients without errors related to dose preparation (inhalation 1), n (%)

128 (84.8)

111 (72.1)

2.16 (1.22–3.80)c

0.007

 Patients without errors related to the inhalation maneuver (inhalation 1), n (%)

117 (77.5)

116 (75.3)

1.13 (0.66–1.92)c

0.657

 Number of HCP-observed errors per patient, mean (SD)

0.50 (0.67)

0.81 (1.10)

0.61 (0.44–0.84)d

0.003

HCP-observed errors reassessed by video expert review (exploratory analysis)

 nb

119

124

 Total number of errors observed by video expert

56

124

 Patients without errors (inhalations 1 & 2), n (%)

79 (66.4)

60 (48.4)

2.11 (1.25–3.54)c

0.005

 Number of video expert assessed errors per patient, mean (SD)

0.47 (0.78)

1.00 (1.26)

0.47 (0.34–0.64)d

< 0.001

  1. BF budesonide formoterol, CI confidence interval, HCP healthcare professional, SD standard deviation
  2. aDerived from Chi-squared test
  3. bNote: Six patients for whom errors were reassessed by independent video review were not included in the full analysis set; data for these patients are not shown in the table
  4. cEstimated from logistic regression models
  5. dEstimated from negative binomial regression model